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Background: Some smokers may benefit from a therapy that combines different nicotine replacement therapies
(NRT) or drugs with different mechanisms of action.
The aim of this study was to determine the efficacy of the combined therapy of varenicline and nicotine patches
versus varenicline monotherapy.
Methods: Three hundred forty-one smokers who smoked 20 or more cigarettes per day were recruited from a
smoking cessation clinic between February 2012 and June 2013. The participants were randomized to receive a
varenicline plus nicotine patch of 21 mg every 24 hours (170) or varenicline plus a placebo patch (171). All of the
smokers received a standard 12-week course of varenicline and an 11-week course of either the placebo patch or
the active patch after the target quit day. Both groups received behavioral support. The primary outcome was
continuous abstinence for weeks 2 through 12 confirmed by exhaled levels of carbon monoxide. Post hoc subgroup
analyses were performed to evaluate the treatment effects for a specific endpoint in subgroups of smokers.
Results: The combination of the nicotine patch with varenicline was not associated with higher rates of continuous
abstinence at 12 weeks (39.1% versus 31.8%; odds ratio (OR) 1.24; 95% confidence interval (CI) 0.8 to 2.6) and
24 weeks (32.8% versus 28.2%; OR 1.17; 95% CI 0.4 to 1.9). When participants were analyzed by subgroups
according to cigarette consumption, the abstinence rates among smokers who smoked more than 29 cigarettes
per day at 12 weeks (OR 1.39; 95% CI 1.2 to 2.5) and 24 weeks (OR 1.46; 95% CI 1.2 to 2.8) were significantly higher
in the combination group. Other post hoc analyses based on level of dependence and previous quit attempts did
not show subgroup differences. No differences between the groups for the reported adverse events were observed
(χ2 value 0.07; P 0.79).
Conclusions: The combination of varenicline with the nicotine patch does not improve abstinence rates at 12 and
24 weeks compared with varenicline used as monotherapy when all smokers were analyzed as a whole,
independent of consumption level.
Trial registration: This study is registered at clinicaltrial.gov (NCT01538394).
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None of the available first-line pharmacological therapies
to treat tobacco dependence have been labelled in Spain
for use in combination with other therapies. Seven first-line
pharmacotherapies that are currently available are rec-
ommended in clinical practice guidelines to treat tobacco
dependence; all of these therapies have been tested to be
effective for increasing tobacco abstinence rates when used
as monotherapies in comparison with a placebo [1]. How-
ever, not all smokers are able to quit with monotherapy.
Some smokers may benefit from a combination therapy
featuring the simultaneous use of different nicotine replace-
ment therapies (NRT) or drugs with different mechanisms
of action (for example, NRT and bupropion). In a recent
meta-analysis conducted by Mills et al. [2], treatment with
NRT did not show a superior effect compared with the
standard treatment of either nicotine patches or varenicline
used as monotherapies. In contrast, in the meta-analysis
by Cahill et al. [3], varenicline was shown to be superior
to both NRT (odds ratio (OR) 1.57; 95% confidence
interval (CI) 1.29 to 1.91) and bupropion (OR 1.59; 95% CI
1.29 to 1.96) but not to an NRT combination (OR 1.06;
95% CI 0.75 to 1.48).
Combination therapy with different drugs may provide
a therapeutic advantage by increasing the serum nicotine
concentrations and capitalizing on the synergy obtained
from two different mechanisms of action [4-6].
Therefore, some smokers may benefit from a com-
bination of varenicline and a NRT. Varenicline may
not fully saturate the nicotinic receptors, and incom-
pletely saturated receptors may lead to only a partial
attenuation of nicotine cravings. If supplemental nicotine
replacement therapy is used, more receptor saturation
is achieved, which may diminish the urge to smoke
more completely.
The evidence from studies with combination therapy
using varenicline and NRT is limited. In a study by
Ebbert et al. [7], a number of pharmacological combin-
ation therapies were compared with a standard treat-
ment in a clinical cohort of residential smokers. The
study showed that the combination of varenicline and
NRT was safe, but no differences were observed from
the group that received standard treatment in terms of
effectiveness.
Recently, a randomized controlled trial [8] observed that
the addition of nicotine patches to varenicline among
smokers who smoked 10 or more cigarettes per day did
not increase the efficacy of varenicline as a monotherapy.
However, a study by Koegelenberg et al. [9] suggested that
the efficacy of varenicline was enhanced by the addition of
nicotine patches.
The aim of this study was to determine the efficacy of
combining varenicline with nicotine patches versus vare-
nicline as monotherapy in smokers who smoked twentyor more cigarettes per day for the last six months. The
primary end point was the continuous abstinence rate
from week two to week twelve of treatment.
Methods
Study design
A randomized placebo-controlled clinical trial was con-
ducted at the Smoking Cessation Clinic situated in the
University Bellvitge Hospital, Barcelona, Spain, between
February 2012 and December 2013.
The center’s ethics committee approved the study.
Participants provided written informed consent.
Participants
The participants were smokers who were seeking treat-
ment in an outpatient smoking cessation clinic between
February 2012 and June 2013. The inclusion criteria
were as follows: being 18 years old or older, having
smoked ≥20 cigarettes daily for the last six months,
providing consent to participate and no period of smoking
abstinence longer than three months in the last year.
Female smokers were eligible provided that they were
not breastfeeding, pregnant (negative pregnancy test)
or at risk of becoming pregnant. The exclusion criteria
were current or past psychotic disorder (schizophrenia),
history of suicide attempts, not understanding the
Spanish language and current or past alcoholism or other
drug addictions.
Smokers who had used nicotine transdermal patches or
varenicline (VRN) in the last six months were excluded.
Smokers with chronic diseases were not excluded.
After a baseline assessment, the participants were
randomly assigned to the treatment arms (varenicline +
nicotine patch or varenicline + placebo patch) in a 1:1
ratio. Randomization was performed using a computer-
generated randomization system, and random numbers
were individually placed into sealed envelopes. An
independent study collaborator preserved the sealed
envelopes and conducted the allocation, allotting one
sealed envelope per patient and opening it in front
of the therapist and the patient. The sample size was
estimated, accepting Type I error alpha = .05 and 80%
power in a two-sided test. Sample size was calculated
based on abstinence rates in previous combination NRT
and varenicline trials. A total of 170 subjects per group
was necessary to detect a statistically significant difference
of ≥15.0% between groups.
Procedures
All participants attended the clinic for baseline assess-
ments one week before the target quit day (TQD). At
the baseline assessment visit, written informed consent
was obtained, the inclusion and exclusion criteria were
reviewed, and the baseline demographic variables and
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and psychosocial characteristics (Beck Depression Inventory
[10] and Hamilton Anxiety Rating scales [11] scores and
social support) and the Fagerstrom Test for Nicotine
Dependence were collected during the baseline inter-
view. All participants started varenicline at the baseline
visit and were randomized to receive either the nicotine
or placebo patches on the TQD. During the treatment
phase, participants visited the clinic at 1, 2, 3, 5, 8, 10,
12 and 24 weeks after the baseline visit.
The Minnesota Nicotine Withdrawal Scale [12], Beck
Depression Inventory [10], Hamilton Anxiety Rating
Scale [11] and the Scale for Suicide Ideation [13] were
recorded at 2, 5, 8, 12 and 24 weeks. At each clinic
visit, the use of the trial therapy, adverse events and
cigarette consumption since the last clinic visit and the
levels of exhaled carbon monoxide were assessed.
Weight and blood pressure were determined at each
visit. At each visit, smokers participated in behavioral
counselling sessions that had been previously standardized.
Sessions lasted 10 to 15 minutes each and were based
on motivational interviewing. The sessions included
practical counselling elements, such as problem solv-
ing and skills training.
Trial medication
Varenicline was used in the standard commercial supply
beginning one week before the TQD: 0.5 mg once daily
for three days, then 0.5 mg twice daily for four days,
followed by 1 mg twice daily for eleven weeks. The smokers
received identical packages of either nicotine (Nicotinell®
21 mg/24 hours) or placebo patches for 11 weeks.
Measures
The primary end point was continuous abstinence defined
as not smoking throughout the follow-up period from week
2 (1 week after the quit date) to week 12 [14,15]. The
criteria for determining continuous abstinence were not
having smoked since week 2 and showing CO concentra-
tions of <10 ppm at 12 weeks. Based on recommendations
from a number of authors, subjects who failed to provide
validation data were considered relapsed [15,16].
The secondary end points were point prevalence, de-
fined as abstinence during the week before the follow-up
visits at 8, 12 and 24 weeks, the continuous abstinence
rate from week 2 through 24, and the incidence of ad-
verse events.
All adverse events were recorded at each visit after
randomization.
Statistical analysis
The statistical analysis was performed on the basis of
intention to treat. All randomized smokers were included
in the analysis. The rates were estimated by including allof the smokers who were allocated into the specific group
in the denominator.
The differences in the percentages were assessed using
the chi-square test, and the means were compared using a
two-sample T-test. A logistic regression model was used
to test the efficacy across the different arms of the study.
The model was adjusted for potential confounding factors,
including gender, age and therapist. The multivariate model
included gender and age as covariates because they have
been [17] related to increased risk of relapse.
Although no differences were observed between
different therapists for the 12-week abstinence rates
(33.9%, 36.8%, 35.6%; χ2 value 0.049; P 0.82), the
counsellor can be a source of bias to control for this
potential source of variation; thus, the therapist was
introduced in the final model.
Post hoc subgroup analyses were performed to evaluate
the treatment effects for a specific end point in sub-
groups of smokers defined by baseline smoking, and
the interaction effect was assessed.
A repeated-measures analysis of variance (ANOVA) was
performed to study the Minnesota Nicotine Withdrawal
Scale (MNWS) scores over time and by group, and
Student’s T-test was used to compare MNWS differences
between the study groups at single points in time.




Figure 1 shows the flowchart for evaluating the study
participants. Of the 438 eligible smokers, 341 (78%) were
included and randomly allocated. Sixty-one smokers did
not meet the inclusion criteria, and 36 smokers refused
to participate. Finally, 170 smokers were assigned to the
varenicline and nicotine patch group, and 171 smokers
were assigned to the varenicline plus placebo patch group.
A total of 243 smokers (71.3%) completed follow-up.
The smokers in the study groups were similar at base-
line, and there were no significant differences between
the two arms (Table 1). The average daily consumption
of cigarettes was 29.2 in the intervention group and 28.7
for the control group (P 0.8).
Primary and secondary end points
Table 2 shows both the continuous and point abstinence
rates. A comparison of the intervention and control
groups for the continuous abstinence rates at 8, 12 and
24 weeks (Table 2) revealed no statistically significant
differences (OR 1.04, 95% CI 0.4 to 2.1; OR 1.24, 95% CI
0.8 to 2.6; and OR 1.17 95% CI 0.4 to 1.9, respectively).
Additionally, when the groups were compared for point
abstinence, the results were similar and not statistically
significant (Table 2).
Figure 1 Flowchart and follow-up.
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the effect of treatment was related to cigarette consumption
(≤29 cigarettes per day (cpd) versus >29 cpd); nicotine
dependence (Fagerstrom test for nicotine dependence
(FTND) score ≤6 versus >6); and previous attempts
(none, 1 to 3 and more than 3).
The post hoc subgroup analyses revealed that the effect of
treatment at 12 and 24 weeks was dependent on cigarette
consumption at baseline (interaction P = 0.02 at 12 weeksand P = 0.02 at 24 weeks). A non-significant interaction
was detected among participants by the level of nicotine
dependence (P = 0.06 at 12 weeks and P = 0.1 at 24 weeks)
and previous attempts (P = 0.4 at 12 weeks and P = 0.6 at
24 weeks).
Analysis between the subgroups was performed based
on the two groups of cigarette smokers, and the rates of
continuous abstinence were significantly higher for the
combined treatment group than for the control group at
Table 1 Baseline characteristics by group
Variables Varenicline + nicotine patch N = 170 Varenicline + placebo N = 171 P-value
Gender Number (%)
Male 95 (55.9%) 102 (59.6%)
Female 75 (44.1%) 69 (40.4%) 0.55a
Age
Mean (±SD) 44.1 (±14.8) 46.2 (±13.1) 0.38b
Cigarettes/day Number (%)
≤29 cig/day 78 (45.9%) 84 (49.1%)
>29 cig/day 92 (54.1%) 87 (50.9%) 0.60a
Previous attempts Number (%)
None 33 (19.4%) 27 (15.8%)
1 73 (42.9%) 67 (39.2%)
2 to 3 44 (25.9%) 60 (35.1%)
>3 20 (11.8%) 17 (9.9%) 0.31a
FTND
Mean (±SD) 6.1 (±1.6) 6.8 (±1.8) 0.9b
aχ2 squared test; bT-test. FTND, Fagerstrom test for nicotine dependence; SD Standard deviation.
Ramon et al. BMC Medicine 2014, 12:172 Page 5 of 9
http://www.biomedcentral.com/1741-7015/12/172week 12 (OR 1.39; 95% CI 1.2 to 2.5) and at week 24
(OR 1.46; 95% CI 1.2 to 2.8) in the subgroup who
smoked more than 29 cpd (Table 3). In contrast, the
differences in the rates among smokers of 29 or fewer
cpd were not significant at weeks 8, 12 and 24.
Nicotine withdrawal
When comparing the mean scores of the MNWS between
the study groups at week 12, the intervention group
showed lower withdrawal than did the control group
(4.6 versus 4.8, F = 1.346; P = 0.05) (Figure 2). The decrease
in MNWS scores in both groups based on consumption
level (Figures 3A and B) during the follow-up period
was statistically significant among smokers who smoked
29 or fewer cpd (P <0.01 in the intervention group and
P <0.05 in the control group) and among smokers ofTable 2 Smoking abstinence by group
Group Continuous abstinence
Abstainers (%) Crude OR (95% CI)
Week 8
Varenicline + nicotine patch (N = 170) 72 (42.2%) 1.08 (0.7 to 1.7)
Varenicline + placebo (N = 171) 69 (40.4%) 1
Week 12
Varenicline + nicotine patch (N = 170) 66 (39.1%) 1.37 (0.8 to 21.)
Varenicline + placebo (N = 171) 54 (31.8%) 1
Week 24
Varenicline + nicotine patch (N = 170) 56 (32.8%) 1.25 (0.8 to 2.0)
Varenicline + placebo (N = 171) 48 (28.2%) 1
aContinuous abstinence from weeks 2 to 8, 12 and 24 weeks; badjusted by age, gendermore than 29 cpd (P <0.01 in the intervention group
and P 0.04 in the control group), as assessed by
repeated-measures ANOVA.
However, when the scores were compared between the
two groups by the cigarette consumption subgroups
(Figure 3A and B), no differences were observed at
each time point among the smokers with a cigarette
consumption ≤29 (Figure 3A) compared with the group of
heavy smokers in which the scores were significantly lower
at 3, 8, 10 and 12 weeks among those who received the
combination therapy (Figure 3B).
Adverse events
Adverse events occurred in 41.3% of smokers in the
combination group compared with 39.7% in the control
group (χ2 value 0.07; P 0.79). The various adverse eventsa Seven-day point-prevalence abstinence
ORb (95% CI) Abstainers (%) Crude OR (95% CI) ORb (95% CI)
1.04 (0.4 to 2.1) 80 (47.2%) 1.06 (0.7 to 1.6) 1.02 (0.3 to 1.6)
1 78 (45.7%) 1 1
1.24 (0.8 to 2.6) 68 (40.2%) 1.37 (0.8 to 2.1) 1.20 (0.7 to 2.1)
1 56 (38.5%) 1 1
1.17 (0.4 to 1.9) 60 (35.1%) 1.28 (0.8 to 2.0) 1.15 (0.4 to 2.0)
1 51 (33.4%) 1 1
and therapist. CI, confidence interval; N, number; OR, odds ratio.
Table 3 Smoking abstinence by group and cigarette consumption
Group Smokers ≤ 29 cigarettes/day Smokers > 29 cigarettes/day
Continuous abstinence Abstainers/N (%) Crude OR (95% CI) ORa (95% CI) Abstainers/N (%) Crude OR (95% CI) ORa (95% CI)
Weeks 2 to 8
Varenicline + nicotine patch 38/78 (48.7%) 1.05 (0.7 to 1.4) 1.0 (0.5 to 1.3) 34/92 (36.9%) 1.13 (0.7 to 1.6) 1.07 (0.6 to 1.8)
Varenicline + placebo 39/84 (46.4%) 1 1 29/87 (33.3%) 1 1
Weeks 2 to 12
Varenicline + nicotine patch 35/78 (43.6%) 1.14 (0.7 to 1.6) 1.0 (0.5 to 1.8) 31/92 (34.8%) 1.44 (0.9 to 2.3) 1.39 (1.2 to 2.5)
Varenicline + placebo 33/84 (39.2%) 1 1 21/87 (24.1%) 1 1
Weeks 2 to 24
Varenicline + nicotine patch 27/78 (34.6%) 0.99 (0.6 to 1.5) 1.0 (0.7 to 1.6) 29/92 (31.5%) 1.52 (1.0 to 2.5) 1.46 (1.2 to 2.8)
Varenicline + placebo 30/84 (35.7%) 1 1 18/87 (20.6%) 1 1
aAdjusted by age, gender and therapist. CI, confidence interval; N, number; OR, odds ratio.
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(χ2 value 0.85; P 0.35), abnormal dreams (χ2 value
0.21; P 0.64) and nausea (χ2 value 0.02; P 0.88) were
the most frequently reported events in both groups.
Headache was more frequently observed in the nico-
tine patch group (4.1% versus 2.6), but the differences
were not statistically significant when both groups
were compared (χ2 value 0.86; P 0.35). No serious ad-
verse events occurred during follow-up.
Five smokers in the combination group discontinued
treatment because of adverse events (three because of
nausea and two because of insomnia), and four smokers
in the control group discontinued (one because ofScore mean









Figure 2 Minnesota nicotine withdrawal scale by intervention group.depressive symptoms, one because of insomnia and two
because of nausea).
No differences between the two groups in relation to
medication adherence throughout follow-up were ob-
served. One participant did not use the patch in the
intervention group, and two from the control group
did not use the patch. All participants in both the
intervention and the control groups used varenicline in
the first four weeks of treatment. One person in the
intervention group but none in the control group failed
to use varenicline between weeks 4 and 12, and three
in the intervention group and two in the placebo group
failed to do so at weeks 8 and 12.w8 w10 w12
VRL+Patch
Figure 3 Minnesota nicotine withdrawal scale by consumption level. One legend for both panels A and B. Under-figures: VRL + PLB:
Varenicline + Placebo; VRL + Patch: Varenicline + Nicotine Patches.
Table 4 Adverse events
Adverse event Varenicline +Nicotine patch Varenicline + Placebo
Number = 170 Number = 171
n (%) n (%)
Insomnia 29 (17.3%) 23 (13.2%)
Nausea 31 (18.3%) 33 (19.1%)
Abnormal dreams 29 (17.4%) 26 (15.1%)
Constipation 15 (8.8%) 13 (7,6%)
Dyspepsia 10 (5.9%) 8 (4.7%)
Headache 7 (4.1%) 4 (2.6%)
Othera 9 (5.3%) 11 (6.4%)
aIrritability, depressive symptoms, fatigue, hypotension.
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The aim of the present study was to assess the efficacy
of the combined use of varenicline and nicotine patches
compared with varenicline alone in smoking cessation.
In this study, the observed results showed that the
combination of varenicline and the nicotine patch was
not associated with an enhanced continuous abstinence
rate at 12 and 24 weeks, as well as with the point preva-
lence abstinence rate at 24 weeks.
The combined use of the nicotine patch and varenicline
compared with varenicline alone resulted in higher rates of
abstinence at 12 and 24 weeks, but only among smokers of
more than 29 cpd.
There are only three studies in the previous literature
that measure the efficacy or effectiveness of combining
varenicline with nicotine patches. An observational study
by Ebbert et al. [7] reported no differences in the 30-day
point prevalence abstinence rate between patients receiving
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NRT at the six-month follow-up and in the reported data
on the safety and tolerability of the combination of vareni-
cline and NRT. A study by Hajek et al. [8], which used the
same method as the present trial with medication started as
per labelling found no effect of the combination treatment
at three months. Koegelenberg et al. [9] found the com-
bination more effective than varenicline alone at three
and six months, but patch use was started two weeks
prior to target quit date. The three studies included
smokers of 10 cigarettes or more, in contrast to this
study in which the participants were smokers of 20 or
more cigarettes. In the Hajek study [8], the continuous
abstinence rate at 12 weeks was similar to that observed
in this study for all smokers in the combination group
as a whole (36% versus 39.1%, respectively), although in
those studies, smokers had lower levels of nicotine de-
pendence and more attempts to stop smoking than did
the smokers in this study. The abstinence rates were
also similar at 12 weeks, which may reflect the existence
of other factors such as the size of the study sample.
The study by Koegelenberg et al. [9] shows higher rates
of abstinence than this study, which may be due to the
inclusion criteria in relation to the amount of consump-
tion (10 or more versus 20 or more cpd), the possible
heterogeneity of the participants and that the nicotine
patch was used for two weeks prior to the TQD. The
results could reflect the effects of ‘nicotine preloading’
rather than any effects of medication combination.
However, in the sub-analysis of the smokers of 29 or
fewer cpd and of those who smoked more than 29 cpd,
the abstinence rates at 12 and 24 weeks were higher and
more significant among the heavy smokers who had re-
ceived the combination therapy. These results are similar
to those of a study of the combination of bupropion and
varenicline for smoking cessation [18].
This study’s sample size was sufficient to detect differ-
ences in the abstinence rates equal to or greater than
15% in one of the groups. The dropout rate in both
groups was similar, and no significant differences were
observed in the participants who withdrew from the
study because of adverse events. In this study, the drop-
outs and the subjects who failed to provide validation
data were considered relapsed [15,16], although not all
of the smokers who dropped out may have actually re-
lapsed, and an underestimation in the rates could have
occurred. However, the number of subjects without in-
formation in each group was similar and was not con-
sidered to be a potential source of bias.
The different usage periods for both of the medications
could represent a possible bias in the results. To control for
these biases, the varenicline and patches were administered
for 11 weeks. Using 21 mg/24 hours patches in combin-
ation therapy did not show an increase in adverse events.The number of patients experiencing headache, insomnia
and nausea was similar in both groups and compar-
able with the rates reported in previous studies using
15 mg/16 hours patches [8,9]. Finally, another poten-
tial limitation is the possibility for bias in the non-
pharmacological interventions. The study involved
three different therapists trained in the standardized
study protocol who were experts in smoking cessation.
However, and although no differences were observed
between different therapists, the counsellor may still
have been a source of bias in this study [19]. To con-
trol for this potential source of variation, the therapist
was introduced in the final model.
Conclusions
In conclusion, the combination of the varenicline with
the nicotine patches does not improve abstinence rates
at 12 and 24 weeks compared with varenicline used as
monotherapy although the combination treatment may
help patients smoking 29 or more cpd. Further research is
needed to confirm this post hoc finding.
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